CTRI/2016/03/006724已完成4 期
A Double blind, Randomized, Placebo controlled, Parallel Group, Prospective, Multicentre Clinical Trial for Evaluation of Efficacy and Safety of Fixed Dose Combination of Minoxidil (5%) plus Finasteride (0.1%) Lipid Solution in Comparison with Minoxidil (5%) Lipid Solution and Finasteride (0.1%) Lipid solution in Adult Male Patients with Androgenetic Alopecia - NA
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male patients in good general physical and mental health, with Androgenetic alopecia.
- •2. Subjects willing to provide written informed consent, indicating that they thoroughly understand the purpose of and procedures required for the study and are willing to participate in the study.
排除标准
- •1. Concomitant dermatological disorders on the scalp other than Androgenetic alopecia.
- •2. Serious cardiovascular diseases (uncontrolled hypertension, angina pectoris, myocardial infarction, etc.), renal diseases or hepatic diseases.
- •3. History of drug hypersensitivity (including contact dermatitis to cosmetics), breast disorders (including gynecomastia, breast enderness) or testicular disorders (testicular growth, testicular pain).
- •4. History of treatment with a systemic or locally acting medication which may interfere with the study objectives, such as Minoxidil treatment in the 06 months prior to dosing, Finasteride treatment in the 12 months prior to dosing, or treatment with other investigational hair growth products in the 06 months prior to dosing
- •5. Ongoing use of prohibited medications (as specified in the protocol)
- •6. Use of any investigational product within 03 months prior dosing of study drug
- •7. Judged by the investigator as otherwise being unsuitable for participation in this trial.
研究者
相似试验
进行中（未招募）
1 期
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying its OnsetMild cognitive impairment due to Alzheimer’s diseaseMedDRA version: 19.0Level: LLTClassification code 10009846Term: Cognitive impairmentSystem Organ Class: 100000004852EUCTR2012-003111-58-DETakeda Development Centre Europe Ltd3,494
进行中（未招募）
不适用
A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients with Mild to Moderate Essential Hypertension.Mild to moderate essential hypertensionMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionEUCTR2007-007516-28-DECytos Biotechnology AG80
进行中（未招募）
1 期
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying its OnsetMild cognitive impairment due to Alzheimer’s diseaseMedDRA version: 18.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 100000004852EUCTR2012-003111-58-GBTakeda Development Centre Europe Ltd3,494
进行中（未招募）
不适用
A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients with Mild to Moderate Essential Hypertension.EUCTR2007-005843-93-DECytos Biotechnology AG60
进行中（未招募）
不适用
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying its OnsetEUCTR2012-003111-58-ITTakeda Development Centre Europe Ltd5,800